Literature DB >> 21971591

Clinical trials: The silent minority--unpublished data on cancer care.

Daniel F Hayes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21971591     DOI： 10.1038/nrclinonc.2011.148

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice.

Authors:  Vincent C Tam; Ian F Tannock; Christine Massey; Jennifer Rauw; Monika K Krzyzanowska
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

Review 2.  Biomarker studies: a call for a comprehensive biomarker study registry.

Authors:  Fabrice Andre; Lisa M McShane; Stefan Michiels; David F Ransohoff; Douglas G Altman; Jorge S Reis-Filho; Daniel F Hayes; Lajos Pusztai
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

3.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

4.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Authors:  Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Petri Bono; Tuomo Alanko; Vesa Kataja; Raija Asola; Tapio Utriainen; Riitta Kokko; Akseli Hemminki; Maija Tarkkanen; Taina Turpeenniemi-Hujanen; Sirkku Jyrkkiö; Martti Flander; Leena Helle; Seija Ingalsuo; Kaisu Johansson; Anna-Stina Jääskeläinen; Marjo Pajunen; Mervi Rauhala; Jaana Kaleva-Kerola; Tapio Salminen; Mika Leinonen; Inkeri Elomaa; Jorma Isola
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

7.  Classical peer review: an empty gun.

Authors:  Richard Smith
Journal:  Breast Cancer Res       Date:  2010-12-20       Impact factor: 6.466
  7 in total
  2 in total

1.  Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

Authors:  Antonio C Wolff; Ann A Lazar; Igor Bondarenko; August M Garin; Stephen Brincat; Louis Chow; Yan Sun; Zora Neskovic-Konstantinovic; Rodrigo C Guimaraes; Pierre Fumoleau; Arlene Chan; Soulef Hachemi; Andrew Strahs; Maria Cincotta; Anna Berkenblit; Mizue Krygowski; Lih Lisa Kang; Laurence Moore; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

2.  Full publication of results initially presented in abstracts.

Authors:  Roberta W Scherer; Joerg J Meerpohl; Nadine Pfeifer; Christine Schmucker; Guido Schwarzer; Erik von Elm
Journal:  Cochrane Database Syst Rev       Date:  2018-11-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.